Health

Yesterday, the UK government released it’s Life Sciences Sector Plan (LSSP). The British government summarized the provisions as follows: 1. Unlocking NHS data to find new cures. Up to £600 million investment to build the world’s most advanced health data system – helping scientists develop better treatments faster. 2. Speeding up clinical trials. Cutting red…

That is the title of my new paper in the Forum for Health Economics and Policy (FHEP) and the subtitle is “Estimating Insurance Value and Risk Preferences in Neurology.” This work is co-authored with Kyi-Sin Than, Jacob Fajnor, Jaehong Kim, Elizabeth Mearns, Stacey Kowal, Thomas Majda and Jakub Hlávka. First, the research uses a multiple…

On this blog we most often talk about health care issues related to chronic and acute conditions, health behaviors and public health. However, there is another dimension that is vital to health: avoiding natural disasters. Unfortunately, natural disasters appear to having an increasing impact in the US across the past decades. Between 1980-2024, 16,941 people…

FDA: Fast-review vouchers to be tied to lower US prices Why FDA rejects drugs (in their own words) Kaiser Health News on prior authorizations. Measles: 1,288 cases in the US this year Impact of ChatGPT on language.

Myself and Kristy Piccinini, PhD from FTI Consulting published a new commentary in The Evidence Base titled “Perspectives from the Healthcare Economist: Why CMS/AHIP’s prior authorization changes won’t hurt payers.” Dr. Shafrin and Dr. Piccinini share their insights in this Guest Column examining the implications of recent CMS/AHIP prior authorization reforms and why these changes are unlikely…